Vivet Therapeutics gains €4.9m for gene therapy development
Betsy Goodfellow | February 2, 2024 | News story | Research and Development | CTX, Neurology, Vivet Therapeutics, funding, gene therapy
Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.
The funding comes from the French Government’s ‘Innovations in biotherapies’ framework, which forms part of the France Health Innovation Plan 2030, and will be distributed over a three-year period.
The company intends to use this funding to develop its gene therapy product VTX-806 as an effective treatment to stop or reverse disease progression over the long-term, and potentially cure the disease in some patients.
Gloria Gonzalez, chief scientific officer at Vivet Therapeutics, commented: “Our commitment to developing treatment options for metabolic disorders is demonstrated by our lead clinical programme, VTX-801, which targets Wilson Disease, alongside a second programme, VTX-806, which is in development as a potential treatment option for CTX patients. Our advanced pipeline highlights our ability to provide strong translational support for rare genetic disorders and patients’ needs, notably with the help of the CTX Alliance and the Spanish CTX patient association.”
Anne Douar, chief operating officer at Vivet Therapeutics, added: “CTX is a progressive, neurodegenerative disorder, that if left untreated can lead to debilitating consequences and a poor prognosis affecting a patient’s lifespan. The funding granted as part of France Health Innovation Plan 2030 will enable Vivet to accelerate the development of a transformative and potentially curative treatment with our gene therapy product VTX-806 for patients with CTX.”
Betsy Goodfellow
Related Content
Rare diseases – spinal muscular atrophy
Spinal muscular atrophy (SMA) is a rare disease characterised by voluntary muscle weakness that can …
Five Facts about spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons …
ProteoNic Biosciences launches platform to enhance cell line productivity
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the …
